# Blinded Evaluation Report — Six Controlled LLM Outputs

All 11 required authoritative files were present. No outside information, web browsing, prior-chat information, or candidate identity information was used.

Structural validation was performed programmatically on the raw files without repair, using JSON parsing and the supplied corrected Draft 2020-12 JSON schema.

*Weighted contributions below are displayed to two decimal places; total scores are calculated from the unrounded contributions.*

---

## Output_01

### Structural Validation

* JSON parse: **PASS**
* Schema validation: **PASS**

### Hard Gates

| Gate | Result     | Evidence / reason                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ---- | ---------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 | **PASS**   | Raw output parses as JSON, validates against the corrected schema, contains the required structures, and uses the allowed `Relevant` and `Medium Priority` labels.                                                                                                                                                                                                                                                                                                                 |
| HG-2 | **PASS**   | Material factual claims, statistics, trends and treatment events are supported by the frozen source. No unavailable quantitative calculation is fabricated.                                                                                                                                                                                                                                                                                                                        |
| HG-3 | **PASS**   | National evidence is kept separate from Medibank interpretation. Member prevalence, claims, coverage, utilisation and financial impact are explicitly treated as unknown or requiring internal investigation.                                                                                                                                                                                                                                                                      |
| HG-4 | **REVIEW** | Material values and periods are otherwise handled accurately, including projections and preliminary mortality data. However, the almost 262,000 DALY burden figure is not explicitly qualified as an estimated/modelled burden result. The output also records only the 30 Jul 2026 update in `last_updated_date`, omitting the separately supplied 21/07/2026 v252.0 page/version signal. Neither omission materially changes the assessment, so REVIEW rather than FAIL applies. |
| HG-5 | **PASS**   | The assessment explicitly addresses clinical significance, utilisation/demand, population affected, magnitude/change and cost, plus trend continuity, private-health relevance, emerging treatment, evidence strength and actionability.                                                                                                                                                                                                                                           |
| HG-6 | **PASS**   | Material findings contain meaningful supporting evidence and accurate source locations, including Figures 1–5 and the relevant health-service/aged-care sections.                                                                                                                                                                                                                                                                                                                  |

### Quality Scores

| Dimension | Score 0–3 | Weight | Weighted contribution | Concise justification                                                                                                                                                                             |
| --------- | --------- | ------ | --------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| QD-1      | **3**     | 15     | 15.00                 | Covers the principal population, mortality, burden, hospital, medication, treatment, aged-care and expenditure signals, with an additional relevant primary-care utilisation finding.             |
| QD-2      | **3**     | 20     | 20.00                 | Finding-level values, periods, denominators, comparators and source paths are highly traceable and generally precise.                                                                             |
| QD-3      | **3**     | 15     | 15.00                 | Provides a balanced synthesis linking the major factors to `Relevant` while repeatedly preserving the national-versus-Medibank boundary.                                                          |
| QD-4      | **3**     | 20     | 20.00                 | `Medium Priority` is carefully justified by balancing substantial burden/utilisation against long-term projections, absence of a recent utilisation shift and lack of Medibank-specific exposure. |
| QD-5      | **2**     | 10     | 6.67                  | Most uncertainty is handled very well, but the DALY estimate/modelled status is not explicit and the secondary page/version metadata signal is omitted.                                           |
| QD-6      | **3**     | 10     | 10.00                 | Follow-ups target Medibank hospital patterns, emerging-treatment uptake/coverage, later AIHW updates and comparison of national versus internal signals.                                          |
| QD-7      | **2**     | 10     | 6.67                  | Clear and usable, but facts and qualifications are repeatedly restated across findings, criteria evidence, rationales and gaps, reducing economy.                                                 |

**Total weighted quality score: 93.33 / 100**

### Material Issues

* The 2024 DALY finding does not explicitly identify the burden result as estimated/modelled.
* The separate 21/07/2026 v252.0 page/version metadata signal is omitted.
* Repetition across evidence, criteria and rationale fields prevents a Strong QD-7 score.

### Material Strengths

* Broad, decision-relevant finding selection without converting national evidence into Medibank facts.
* Strong treatment of projections, mortality caveats, principal-diagnosis hospital scope and expenditure estimates.
* Priority reasoning closely balances clinical importance, utilisation, cost, emerging treatments, immediacy and missing Medibank evidence.
* Follow-ups are concrete and directed toward resolvable internal information gaps.

---

## Output_02

### Structural Validation

* JSON parse: **PASS**
* Schema validation: **PASS**

### Hard Gates

| Gate | Result     | Evidence / reason                                                                                                                                                                                                                                                                                       |
| ---- | ---------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 | **PASS**   | Raw JSON parses and validates without repair, and all relevance/priority labels are allowed.                                                                                                                                                                                                            |
| HG-2 | **PASS**   | Findings and quantitative content are traceable to the frozen source. No unsupported calculation or source-grounded factual claim was identified. Rounded quantities represented numerically remain explicitly qualified in their associated unit/text.                                                 |
| HG-3 | **PASS**   | National expenditure, utilisation and private treatment access are not presented as Medibank claims, coverage or financial exposure.                                                                                                                                                                    |
| HG-4 | **REVIEW** | Estimates, projections, preliminary mortality, aged-care recency and other caveats are generally strong. The almost 262,000 DALY finding is nevertheless not explicitly identified as an estimated/modelled burden result. This is a local qualification omission matching the rubric's REVIEW example. |
| HG-5 | **PASS**   | All core factors and relevant supplementary factors are explicitly and contextually assessed.                                                                                                                                                                                                           |
| HG-6 | **PASS**   | Supporting evidence and source paths are specific and auditable; no fabricated source location was identified.                                                                                                                                                                                          |

### Quality Scores

| Dimension | Score 0–3 | Weight | Weighted contribution | Concise justification                                                                                                                                                            |
| --------- | --------- | ------ | --------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| QD-1      | **3**     | 15     | 15.00                 | Eight findings efficiently cover all major decision-driving dimensions needed for relevance and priority.                                                                        |
| QD-2      | **3**     | 20     | 20.00                 | Excellent auditability, including exact versus rounded prevalence/expenditure values and relevant denominator/scope details.                                                     |
| QD-3      | **3**     | 15     | 15.00                 | Relevance reasoning integrates clinical burden, service use, scale, expenditure and emerging treatment while clearly separating investigation from established Medibank effects. |
| QD-4      | **3**     | 20     | 20.00                 | Priority reasoning explicitly balances strong national signals against long-duration change, absence of abrupt recent shifts and missing organisation-specific evidence.         |
| QD-5      | **2**     | 10     | 6.67                  | Extensive uncertainty handling is present, but the DALY modelled/estimated status is not explicitly preserved.                                                                   |
| QD-6      | **3**     | 10     | 10.00                 | Follow-ups are specific to internal utilisation/cost patterns, treatment access, later regulatory developments and resolution of known data gaps.                                |
| QD-7      | **2**     | 10     | 6.67                  | Clear but lengthy, particularly through the extensive information-gap and qualification material after those limitations have already been discussed elsewhere.                  |

**Total weighted quality score: 93.33 / 100**

### Material Issues

* The burden-of-disease DALY result lacks an explicit estimated/modelled qualification.
* The extensive gap and caveat material creates some unnecessary repetition.

### Material Strengths

* Strong retention of source qualifications, including exact/rounded differences and the Figure 5 8-versus-9-row discrepancy.
* Very clear Medibank evidence boundary.
* Well-calibrated `Medium Priority` reasoning with no invented prioritisation thresholds.
* High-quality, evidence-linked investigation suggestions.

---

## Output_03

### Structural Validation

* JSON parse: **PASS**
* Schema validation: **PASS**

### Hard Gates

| Gate | Result     | Evidence / reason                                                                                                                                                                                                                        |
| ---- | ---------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 | **PASS**   | Valid raw JSON, corrected-schema compliant and restricted to allowed category labels.                                                                                                                                                    |
| HG-2 | **PASS**   | Source findings, treatment events and quantitative values are supported by the snapshot; no fabricated metric or unsupported source-grounded fact was identified.                                                                        |
| HG-3 | **PASS**   | Public-source facts and Medibank interpretation remain clearly separated. Private treatment access is not equated with insurance reimbursement or Medibank coverage.                                                                     |
| HG-4 | **REVIEW** | Estimate/projection distinctions, mortality preliminariness, principal-diagnosis scope and older aged-care periods are retained. The 262,000 DALY result, however, is not explicitly identified as an estimated/modelled burden measure. |
| HG-5 | **PASS**   | Core Medibank factors and supported supplementary factors are all substantively integrated into the assessment.                                                                                                                          |
| HG-6 | **PASS**   | Findings are readily traceable to appropriate sections/Figures 1–5; source locations are not invented.                                                                                                                                   |

### Quality Scores

| Dimension | Score 0–3 | Weight | Weighted contribution | Concise justification                                                                                                                                      |
| --------- | --------- | ------ | --------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------- |
| QD-1      | **3**     | 15     | 15.00                 | Major evidence across population, mortality, burden, hospital utilisation, medicines, treatment, aged care and spending is captured.                       |
| QD-2      | **3**     | 20     | 20.00                 | Strong claim-to-evidence linkage with relevant periods, denominators and source locations preserved.                                                       |
| QD-3      | **3**     | 15     | 15.00                 | The rationale synthesises the agreed factors and makes internal Medibank verification a condition rather than asserting organisation-specific impacts.     |
| QD-4      | **3**     | 20     | 20.00                 | Medium priority is proportionate to the evidence and explicitly distinguishes long-term/historical signals from demonstrated immediate Medibank change.    |
| QD-5      | **2**     | 10     | 6.67                  | Very good treatment of projections, preliminary data, unavailable table detail and known gaps, with the DALY qualification as the notable omission.        |
| QD-6      | **3**     | 10     | 10.00                 | Follow-up questions directly address hospital claims, treatment coverage/utilisation and future source updates.                                            |
| QD-7      | **2**     | 10     | 6.67                  | Clear overall, but prevalence is split across two closely related findings and several audit qualifications reappear in the gap list, reducing efficiency. |

**Total weighted quality score: 93.33 / 100**

### Material Issues

* The disease-burden figure is not explicitly described as an estimated/modelled result.
* Closely related prevalence evidence is split across two findings and some audit limitations are repeated later, reducing concision.

### Material Strengths

* Strong quantitative and temporal fidelity, particularly around projections versus estimates.
* Explicit handling of Medibank-specific unknowns.
* Good balancing of national burden, utilisation, expenditure, treatment developments and lack of demonstrated immediacy.
* Monitoring recommendations are specific and evidence-linked.

---

## Output_04

### Structural Validation

* JSON parse: **PASS**
* Schema validation: **PASS**

### Hard Gates

| Gate | Result     | Evidence / reason                                                                                                                                                                                                                                                          |
| ---- | ---------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 | **PASS**   | Programmatic JSON parsing and corrected-schema validation both succeed without modification. Labels comply with the allowed enums.                                                                                                                                         |
| HG-2 | **PASS**   | All material factual findings and numerical claims checked are supported by the frozen source; no unavailable calculation is invented.                                                                                                                                     |
| HG-3 | **PASS**   | Medibank implications are expressly presented as matters for investigation. National utilisation, spending and private access are not converted into Medibank facts.                                                                                                       |
| HG-4 | **REVIEW** | Quantitative values, periods, projections, mortality caveats and utilisation scope are otherwise accurately preserved. The almost 262,000 DALY finding is not explicitly qualified as estimated/modelled, which is a non-material qualification omission under the rubric. |
| HG-5 | **PASS**   | The five core factors and relevant supplementary considerations are explicitly assessed and integrated into the final judgement.                                                                                                                                           |
| HG-6 | **PASS**   | Material findings have meaningful supporting evidence and accurate section/Figure locations.                                                                                                                                                                               |

### Quality Scores

| Dimension | Score 0–3 | Weight | Weighted contribution | Concise justification                                                                                                                                                   |
| --------- | --------- | ------ | --------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| QD-1      | **3**     | 15     | 15.00                 | Captures all major decision-relevant signals, including medication and antipsychotic utilisation as separately scoped findings.                                         |
| QD-2      | **3**     | 20     | 20.00                 | Values, periods, denominators, comparators and evidence paths are clear and readily auditable.                                                                          |
| QD-3      | **3**     | 15     | 15.00                 | Provides a balanced relevance synthesis with explicit limitations on what the evidence can establish for Medibank.                                                      |
| QD-4      | **3**     | 20     | 20.00                 | Strong Medium-Priority calibration across burden, service utilisation, spending, projection horizon, treatment developments and absence of near-term Medibank evidence. |
| QD-5      | **2**     | 10     | 6.67                  | Main estimate/projection, mortality, hospital, aged-care and private-access caveats are handled well; the DALY estimate/model status remains unstated.                  |
| QD-6      | **3**     | 10     | 10.00                 | Follow-ups focus on internal hospital patterns, treatment uptake, future AIHW evidence and age-specific utilisation/cost questions.                                     |
| QD-7      | **3**     | 10     | 10.00                 | The structured assessment remains focused and directly usable, with limited ancillary audit detail and no material evidence sacrificed for concision.                   |

**Total weighted quality score: 96.67 / 100**

### Material Issues

* The 2024 DALY result is not explicitly identified as estimated/modelled; this produces the HG-4 REVIEW and limits QD-5 to Acceptable.

### Material Strengths

* Comprehensive coverage of the important assessment dimensions without requiring exhaustive transcription.
* Strong source-to-claim traceability.
* Clear and disciplined distinction between national evidence and internal Medibank questions.
* Carefully calibrated priority and focused follow-up recommendations.
* Efficient structured presentation while retaining material caveats.

---

## Output_05

### Structural Validation

* JSON parse: **PASS**
* Schema validation: **PASS**

### Hard Gates

| Gate | Result     | Evidence / reason                                                                                                                                                                                                                            |
| ---- | ---------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HG-1 | **PASS**   | Raw JSON parses and validates against the corrected schema; required structures and allowed labels are present.                                                                                                                              |
| HG-2 | **PASS**   | Reported population, mortality, burden, medicine, hospital, aged-care, expenditure and treatment claims are source-supported; no fabricated quantitative calculation was identified.                                                         |
| HG-3 | **PASS**   | National/public evidence is not represented as proving Medibank member or claims outcomes. Private access is appropriately separated from coverage or reimbursement.                                                                         |
| HG-4 | **REVIEW** | Projections, mortality preliminariness, principal-diagnosis scope, residential-care recency and expenditure estimation are otherwise handled accurately. The 262,000 DALY burden finding lacks an explicit estimated/modelled qualification. |
| HG-5 | **PASS**   | Assessment demonstrably applies all five agreed core factors and the relevant supplementary factors.                                                                                                                                         |
| HG-6 | **PASS**   | Material claims are traceable to accurate source sections and figures, with no fabricated source paths identified.                                                                                                                           |

### Quality Scores

| Dimension | Score 0–3 | Weight | Weighted contribution | Concise justification                                                                                                                                                |
| --------- | --------- | ------ | --------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| QD-1      | **3**     | 15     | 15.00                 | Eight findings cover the principal clinical, utilisation, population, change, cost and emerging-treatment evidence required for the judgement.                       |
| QD-2      | **3**     | 20     | 20.00                 | Supporting evidence is detailed, accurately contextualised and tied to clear source locations.                                                                       |
| QD-3      | **3**     | 15     | 15.00                 | Relevance reasoning is well integrated and consistently marks Medibank impacts as hypotheses requiring internal evidence.                                            |
| QD-4      | **3**     | 20     | 20.00                 | Priority reasoning distinguishes strong burden/current service signals from projected or historical change and explicitly addresses absent Medibank-specific impact. |
| QD-5      | **2**     | 10     | 6.67                  | Most important limitations are systematically represented, but the disease-burden estimate/model qualification is absent.                                            |
| QD-6      | **3**     | 10     | 10.00                 | Provides targeted internal checks, future-source monitoring, treatment investigation and attention to identified primary/community-care gaps.                        |
| QD-7      | **2**     | 10     | 6.67                  | Clear but somewhat over-detailed: the five follow-ups and extensive information-gap list repeat several limitations already stated in the assessment.                |

**Total weighted quality score: 93.33 / 100**

### Material Issues

* The DALY finding omits explicit estimated/modelled status.
* Repetition of limitations in criteria judgements, priority reasoning and the long information-gap list reduces output efficiency.

### Material Strengths

* Strong coverage of all principal decision-driving signals.
* Particularly clear treatment of projection status, mortality caveats and national-versus-Medibank cost distinctions.
* Strong contextual use of Medibank's agreed factors.
* Useful, specific follow-up questions rather than unsupported recommendations.

---

## Output_06

### Structural Validation

* JSON parse: **PASS**
* Schema validation: **PASS**

### Hard Gates

| Gate | Result     | Evidence / reason                                                                                                                                                                                                                                      |
| ---- | ---------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| HG-1 | **PASS**   | The raw output parses and programmatically validates against the supplied schema with allowed relevance and priority labels.                                                                                                                           |
| HG-2 | **PASS**   | All material findings checked—including the additional MBS, aged-care assessment and data-gap findings—are supported by the frozen source. No unsupported calculation is introduced.                                                                   |
| HG-3 | **PASS**   | The assessment repeatedly states that member prevalence, claims, benefits, coverage and financial effects are not established by the national evidence.                                                                                                |
| HG-4 | **REVIEW** | Projection, preliminary-mortality, hospital-scope, aged-care recency and spending qualifications are preserved. The almost 262,000 DALY result remains unqualified as an estimated/modelled burden measure, producing a local REVIEW under the rubric. |
| HG-5 | **PASS**   | All agreed core factors and supported supplementary factors are assessed contextually and feed into the relevance/priority decisions.                                                                                                                  |
| HG-6 | **PASS**   | The ten findings remain traceable to source sections/Figures and the data-gap headings; no fabricated source location was identified.                                                                                                                  |

### Quality Scores

| Dimension | Score 0–3 | Weight | Weighted contribution | Concise justification                                                                                                                                                   |
| --------- | --------- | ------ | --------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| QD-1      | **3**     | 15     | 15.00                 | Captures all principal signals and adds source-supported primary-care, aged-care assessment and data-availability evidence that remains decision relevant.              |
| QD-2      | **3**     | 20     | 20.00                 | Highly detailed source linkage with good preservation of populations, denominators, reference periods and scope.                                                        |
| QD-3      | **3**     | 15     | 15.00                 | Relevance reasoning provides a balanced synthesis and consistently distinguishes public evidence from questions for internal Medibank investigation.                    |
| QD-4      | **3**     | 20     | 20.00                 | Medium priority is carefully calibrated: high national burden and service use are balanced against long-term/historical change and absent near-term Medibank impact.    |
| QD-5      | **2**     | 10     | 6.67                  | Extensive uncertainty and missingness handling is present, but the DALY estimate/model qualification remains missing.                                                   |
| QD-6      | **3**     | 10     | 10.00                 | Follow-ups directly target admissions/LOS, emerging-treatment utilisation, future source updates and translation of national trends into internal demand/cost evidence. |
| QD-7      | **2**     | 10     | 6.67                  | Clear and well organised but extensive; the separate source-grounded data-gap finding is partly repeated in `information_gaps` and later reasoning.                     |

**Total weighted quality score: 93.33 / 100**

### Material Issues

* The disease-burden DALY value lacks explicit estimated/modelled status.
* Data-availability limitations are represented both as a source-grounded finding and again in the assessment/gap fields, creating some duplication.

### Material Strengths

* Broad yet source-supported finding coverage, including useful additional evidence not required by the reference set.
* Excellent national-versus-Medibank boundary discipline.
* Strong multi-factor relevance and priority synthesis.
* Specific follow-ups tied directly to the most important unresolved Medibank questions.

---

# Blinded Summary Table

| Output    | Hard Gate FAIL count | Hard Gate REVIEW count | Quality score /100 |
| --------- | -------------------: | ---------------------: | -----------------: |
| Output_01 |                    0 |                      1 |              93.33 |
| Output_02 |                    0 |                      1 |              93.33 |
| Output_03 |                    0 |                      1 |              93.33 |
| Output_04 |                    0 |                      1 |              96.67 |
| Output_05 |                    0 |                      1 |              93.33 |
| Output_06 |                    0 |                      1 |              93.33 |
